Polymer‐assisted regeneration therapy with Atrisorb® barriers in human periodontal intrabony defects

Abstract

C-M: Polymer-assisted regeneration therapy with Atrisorb s barriers in human periodontal intrabony defects. AbstractAim: This study compared clinical results of 40 periodontal osseous defects treated by two types of absorbable barrier materials. Material and Methods: Thirty patients (23 males and seven females) suffering from moderate to advanced periodontitis (with comparable osseous defects) were randomly assigned to receive either Atrisorb s barrier (n 5 22; group A) or Resolut XT s barrier (n 5 18; group B) therapy. Periodontal phase I treatment and oral hygiene instruction were performed before periodontal surgery. Papillary preservation, partial thickness flap, citric acid root conditioning, and decortication procedures were applied during the operation. Bone defects were filled with demineralized freeze-dried bone allograft and minocycline mixture (4:1 ratio). Postoperative care included 0.10% chlorhexidine rinse daily and antibiotic medication for 2 weeks. Clinical assessments including probing depth (PD), clinical attachment level (CAL), gingival recession (GR), plaque index (PlI), gingival index (GI), and radiographic examinations were taken at the baseline, preoperatively and at 3 and 6 months after regenerative surgery. Results: Six months following therapy, both Atrisorb s and Resolut XT s groups had achieved comparable clinical improvement in pocket reduction (3.9 versus 4.4 mm), attachment tissue gain (clinical attachment gain; 3.5 versus 3.6 mm), and reduction in the GI and in the PlI. Within-group comparisons showed significant attachment gain and pocket reduction between baseline data and those at both 3 and 6 months postoperatively (po0.01). There were no statistically significant differences in any measured data between groups A and B. Conclusions: The results of this study indicate that a comparable and favorable regeneration of periodontal defects can be achieved with both Atrisorb s and Resolut XT s barriers. Further long-term study and histologic observations of tissue healing are needed to evaluate whether Atrisorb s is promising for clinical use.

Evaluation of an in situ formed synthetic hydrogel as a biodegradable membrane for guided bone regeneration

“…Although this material is available as a fluid that can precipitate in situ by adding water (Rosen & Reynolds 1999), in the majority of the studies a membrane made of the polymer was formed extrao-rally, before it was applied to cover the periodontal defect Jepsen et al 2000). Generally speaking, significant amounts of periodontal tissue regeneration have been reported, when using this membrane (Polson et al 1995;Hou et al 2004).…”

Biomaterials for periodontal regeneration

“…And the second regeneration of membrane is absorbable and currently popular for periodontal regeneration since there is minimal membrane exposure and no need of membrane retrieval 76 . But the bioabsorbable membrane may provide a greater bone area than the non-resorbable membrane 77 …”

Letter to the Editor, “BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction”

“…Interestingly, the efficacy of bromodomain inhibition for this indication may already be clinically evident, as existing dental barrier membranes (e.g., Atrisorb and InionGTR) contain high concentrations (up to 60% v/v) of the solubilizing excipient, N-methyl-2-pyrrolidone (NMP; Hou et al 2004;Pirhonen et al 2006).…”